M. Catellani
University of Milan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Catellani.
PLOS ONE | 2017
L. Boeri; M. Fontana; Andrea Gallioli; Stefano Paolo Zanetti; M. Catellani; F. Longo; B. Mangiarotti; E. Montanari
The role of rectal culture-guided antimicrobial prophylaxis (TAP) in reducing infectious complications (IC) after transrectal-ultrasound prostate biopsy (TRUSPBx) is conflicting. We assessed the prevalence of IC in a cohort of men at high risk for IC submitted to TRUSPBx and treated with either TAP or empirical prophylaxis (EAP). Data from 53 patients at high risk for IC undergoing TRUSPBx were collected. Patients who did not receive a rectal swab (RS) were treated with EAP with fluoroquinolones (FQs). Of those who received the RS, patients with FQ-susceptible organisms received ciprofloxacin while those with FQ-resistant organisms received TAP. Office visits were scheduled to investigate the rate of complication at day 7 and 30 after TRUSPBx. Comorbidities were scored with the Charlson Comorbidity Index (CCI). Descriptive statistics and logistic regression models detailed the association between clinical parameters and IC rate. Out of 53 men, 17 (32.1%) had RS while 36 (67.9%) did not. All RS cultures were positive for E. Coli and 4 (23.5%) reported FQ-resistant pathogens. Considering risk factors for IC, no difference was found in terms of CCI, rate of diabetes, UTIs or recent antibiotic utilization between groups. Overall, 12 (22.6%) men reported IC, with a greater proportion of them belonging to the group treated with EAP (30.6% vs 5.9%; p = 0.045). Of these, 9 (25.0%) patients, all treated with EAP, developed post biopsy UTIs. E. Coli sustained all UTIs and 7 (77.7%) were FQ resistant. At multivariable analysis, CCI≥1, a history of UTIs/prostatitis and recent antibiotic utilization (all p<0.04) were the most powerful predictors for ICs. In conclusion, we found that compared to EAP, TAP significantly reduces ICs, in men at high risk for post TRUSPBx IC. Patients at risk for IC, especially those with recent antibiotic utilization, CCI≥1 and a history of UTIs/prostatitis before biopsy, could benefit from TAP.
Archivio Italiano di Urologia e Andrologia | 2016
Stefano Paolo Zanetti; L. Boeri; M. Catellani; Andrea Gallioli; A. Trinchieri; Kemal Sarica; E. Montanari
OBJECTIVEnA wide selection of both anterograde and retrograde mini-invasive procedures exist for stones treatment. The 2016 European Association of Urology (EAU) guidelines still dont univocally define a best option. Our purpose is to give an overview on some European Stone Centers customs and to compare real life clinical practice with statements of opinion leaders and Guidelines.nnnMATERIALS AND METHODSnIn 2015 we performed a survey in 3 step about the spread of retrograde intrarenal surgery (RIRS) and percutaneous nephrolithotomy (PCNL) techniques among EAU Section of Urolithiasis (EULIS) members. The 1st and 2nd steps dealt with the definition of EULIS urologist and department by collecting personal opinions about the endoscopic techniques. The third step was about clinical results. This paper presents data from the first two steps.nnnRESULTSnNinety-one people answered. Out of them, 80% are European and 42% work in Centres fully dedicated to stone treatment. In particular, 50% of responders perform more than 80 RIRS/year, 25% more than 80 PCNL/year, 48% more than 100 extracorporeal shock wave lithotripsy (SWL)/year. RIRS is mainly used to treat stones < 2 cm both as primary treatment and after SWL failure. 73% dont perform routine pre-stenting and 66% ordinarily use a ureteral sheath. Hospital stay for RIRS is 24h for 70% of responders. Regular PCNL is performed by 87% of the responders, MiniPCNL by 58%, Ultra-MiniPCNL by 23% and MicroPCNL by 28%. Pneumatic balloon dilation is the favourite dilation technique (49%). 37% of responders perform PCNL always in the supine position, 21% always in the prone one. Almost all the responders agree about using Mini, Ultra-Mini and MicroPCNL for 1-2 cm stones. Approximately 50% also use MiniPCNL for stones > 2 cm.nnnCONCLUSIONnour survey confirms the great heterogeneity existing in stones treatment techniques in daily practice.
Urologia Internationalis | 2018
Stefano Luzzago; Gennaro Musi; M. Catellani; Andrea Russo; Ettore Di Trapani; Francesco Mistretta; R. Bianchi; Gabriele Cozzi; Andrea Conti; Paola Pricolo; Matteo Ferro; D.V. Matei; Vincenzo Mirone; Giuseppe Petralia; Ottavio De Cobelli
Background: To evaluate the role of confirmatory multiparametric magnetic resonance imaging (mpMRI) of the prostate at the time of Active Surveillance (AS) enrollment to reduce disease misclassification. Materials: From 2012 to 2016, 383 patients with low-risk disease respecting Prostate Cancer Research International AS criteria underwent confirmatory 1.5-T mpMRI. AS was proposed to patients with Prostate Imaging and Report and Data System (PI-RADS) score ≤3 and no extraprostatic extension (EPE), whereas patients with PI-RADS score ≥4 and/or EPE were treated actively. Kaplan-Meier analyses quantified progression-free survival (PFS) in patients enrolled in the AS program. Logistic regression analyses tested the association between confirmatory mpMRI and clinically significant prostate cancer (csPCa) at radical prostatectomy (RP). Diagnostic performance of mpMRI was calculated in patients submitted to immediate RP. Results: PFS rate was 99, 90 and 86% at 1, 2 and 3 years respectively. At multivariable analysis, PI-RADS 3, PI-RADS 4, PI-RADS 5 and EPE increased the probability of having csPCa at immediate RP (PI-RADS 3 [OR] 1.2, p = 0.26; PI-RADS 4 [OR] 5.1, p = 0.02; PI-RADS 5 [OR] 6.7; p = 0.009; EPE [OR] 11.8, p < 0.001). Confirmatory mpMRI showed sensibility, specificity, positive predictive value and negative predictive value of 85, 55, 68 and 76% respectively. Conclusions: MpMRI at the time of AS enrollment reduces the misclassification rate of csPCa. We suggest to perform target biopsies in patients with PI-RADS score 3 and 4 lesions.
European urology focus | 2018
Jaap D. Legemate; Guido Kamphuis; Jan Erik Freund; Joyce Baard; Stefano Paolo Zanetti; M. Catellani; Harry W. Oussoren; Jean de la Rosette
BACKGROUNDnFlexible ureteroscopy is an established treatment modality for evaluating and treating abnormalities in the upper urinary tract. Reusable ureteroscope (USC) durability is a significant concern.nnnOBJECTIVEnTo evaluate the durability of the latest generation of digital and fiber optic reusable flexible USCs and the factors affecting it.nnnDESIGN, SETTING, PARTICIPANTSnSix new flexible USCs from Olympus and Karl Storz were included. The primary endpoint for each USC was its first repair. Data on patient and treatment characteristics, accessory device use, ureteroscopy time, image quality, USC handling, disinfection cycles, type of damage, and deflection loss were collected prospectively.nnnINTERVENTIONnUreteroscopy.nnnOUTCOME MEASUREMENTS AND STATISTICAL ANALYSISnUSC durability was measured as the total number of uses and ureteroscopy time before repair. USC handling and image quality were scored. After every procedure, maximal ventral and dorsal USC deflection were documented on digital images.nnnRESULTS AND LIMITATIONSnA total of 198 procedures were performed. The median number of procedures was 27 (IQR 16-48; 14h) for the six USCs overall, 27 (IQR 20-56; 14h) for the digital USCs, and 24 (range 10-37; 14h) for the fiber optic USCs. Image quality remained high throughout the study for all six USCs. USC handling and the range of deflection remained good under incremental use. Damage to the distal part of the shaft and shaft coating was the most frequent reason for repair, and was related to intraoperative manual forcing. A limitation of this study is its single-center design.nnnCONCLUSIONSnThe durability of the latest reusable flexible USCs in the current study was limited to 27 uses (14h). Damage to the flexible shaft was the most important limitation to the durability of the USCs evaluated. Prevention of intraoperative manual forcing of flexible USCs maximizes their overall durability.nnnPATIENT SUMMARYnCurrent flexible ureteroscopes proved to be durable. Shaft vulnerability was the most important limiting factor affecting durability.
Clinical Genitourinary Cancer | 2018
Stefano Luzzago; Giuseppe Petralia; Gennaro Musi; M. Catellani; Sarah Alessi; Ettore Di Trapani; Francesco Mistretta; Alessandro Serino; A. Conti; Paola Pricolo; Sebastiano Nazzani; Vincenzo Mirone; D.V. Matei; E. Montanari; Ottavio De Cobelli
Purpose: To understand the multiparametric magnetic resonance imaging (mpMRI) interreader agreement between radiologists of peripheral and academic centers and the possibility to avoid prostate biopsies according to magnetic resonance imaging second opinion. Patients and Methods: This prospective observational study enrolled 266 patients submitted to mpMRI at nonacademic centers for cancer detection or at active surveillance begin. Images obtained were reviewed by 2 unblinded radiologists with 8 and 5 years’ experience on mpMRI, respectively. We recorded Prostate Imaging Reporting and Data System (PI‐RADS) v2 categories and management strategy changes after mpMRI rereadings. Interreader agreement was assessed by the Cohen kappa. For mpMRI second opinion, positive predictive value and negative predictive value were calculated. Results: In the original readings, no lesions (ie, PI‐RADS < 2) were observed in 17 cases (6.5%). Reported index lesion (IL) PI‐RADS category was 2 in 23 (8.5%), 3 in 85 (32%), 4 in 98 (37%), and 5 in 13 (5%) men, respectively. It is noteworthy that in 30 examinations (11%), an IL was recognized by radiologists, but a suspicious score was not assigned. According to first reading of mpMRI, initial clinical strategy included performing a targeted (226; 85%) or a systematic biopsy (8; 3%), scheduling the patient to an active surveillance program without repeat biopsy (10; 4%), or monitoring prostate‐specific antigen without prostate sampling (22; 8%). The mpMRI rereads did not change IL PI‐RADS category in 91 cases (38.5%), although in 20 (8.5%) and 125 (53%) IL PI‐RADS was upgraded or downgraded, respectively (&kgr; = 0.23). The clinical management changed in 113 patients (48%) (&kgr; = 0.2). Overall, 102 targeted biopsies (51%) were avoided and 72 men (34.5%) were not submitted to biopsy after mpMRI second opinion. Positive predictive value and negative predictive value of the mpMRI rereading were 58% and 91%, respectively. Major limitations of the study are limited‐time follow‐up and the lack of a standard of reference for some men, who were not submitted to biopsy according to mpMRI second opinion. Conclusion: There is an important level of discordance between mpMRI reports. According to imaging second opinion, roughly half of targeted biopsies could be avoidable and 34.5% of men could skipped prostate sampling. Prospective randomized trials are needed to confirm our findings. MICRO‐ABSTRACT In this prospective observational study, we observed a significant level of discordance between multiparametric magnetic resonance imaging of the prostate reports in peripheral and subspecialized centers. If confirmed by further prospective randomized trials, multiparametric magnetic resonance imaging second opinion by expert radiologists could become a useful tool to deliver the best management for patients, avoiding 52% of targeted and 33.5% of total biopsies.
Asian Journal of Urology | 2018
Luca Carmignani; Maria Chiara Clementi; Claudia Signorini; Gloria Motta; Sebastiano Nazzani; F. Palmisano; Elisa De Lorenzis; M. Catellani; Alessandro Mistretta Francesco; Andrea Conti; V. Tringali; Maria Costa Beatrice; Damiano Vizziello
Objective We aimed to determine safety and feasibility of thulium laser transurethral vapoenucleation of prostate (ThuVEP) for treatment of obese patients affected by benign prostatic hyperplasia (BPH). Methods We retrospectively analysed data of 452 patients with BPH who underwent ThuVEP from February 2012 to March 2016 in a single center. Patients were divided into three groups according to body mass index (BMI, kg/m2): Normal weight (18.5 ≤ BMIu202f<u202f25; Group A), overweight (25 ≤ BMIu202f<u202f30; Group B) and obese (BMIu202f≥u202f30; Group C), for a total of 412 patients evaluable for this study. Preoperative total serum prostate-specific antigen (PSA), digital rectal examination of the prostate, transrectal ultrasound (TRUS), renal ultrasound, urine culture, uroflowmetry, International Prostate Symptoms Score (IPSS), and Quality of Life (QoL) score were analyzed. Post-operative complications, hospital stay and days of catheterization, questionnaires and uroflowmetry at 1 and 3 months after surgery were evaluated. Preoperative data, surgical outcomes, complication rate and clinical outcomes were compared between groups. Results The median age of patients was 69 years (Interquartile Range [IQR 10]). The preoperative median IPSS among groups was 19 (IQR 8.75), 20 (IQR 10), and 18 (IQR 10) respectively. At 1 and 3 months of follow-up, this value was 8 (IQR 7), 8 (IQR 4), 7 (IQR 5) and 5 (IQR 6.25), 5 (IQR 6), 6 (IQR 5), respectively (all p between groupsu202f>u202f0.05). There was no statistically significant difference among three groups as for hospital stay and days of catheterization (p > 0.05). Conclusion Our results showed that ThuVEP was safe and feasible even in overweight patients with substantially enlarged prostate.
European Urology Supplements | 2017
Gennaro Musi; A. Conti; Andrea Russo; F.A. Mistretta; A. Serino; V. Tringali; M. Catellani; G. Cozzi; R. Bianchi; M. Delor; Matteo Ferro; Victor Matei; O. De Cobelli
Introduction and Objectives Traditional surgical treatment of penile carcinoma was amputation of the glans, resulting in organ dysfunction and disfigurement, with a strong impact on patient’s quality of life. Several conservative treatment modalities have been introduced with the goal of achieving conservative treatment. We present the initial experience with thulium laser excision of early stage penile lesions.
European Urology Supplements | 2017
L. Boeri; M. Fontana; A. Gallioli; S.P. Zanetti; M. Catellani; E. De Lorenzis; F. Palmisano; F. Longo; E. Montanari
The Journal of Urology | 2018
Jaap D. Legemate; Guido Kamphuis; Jan Erik Freund; Joyce Baard; Stefano Paolo Zanetti; M. Catellani; Harry W. Oussoren; Jean de la Rosette
European Urology Supplements | 2018
D.V. Matei; F.A. Mistretta; Vanna Zanagnolo; M. Catellani; Mihai Dorin Vartolomei; Nicolae Crisan; Matteo Ferro; Luca Bocciolone; Angelo Maggioni; I. Coman; O. De Cobelli